BridgeMD
Preoperative Lugol’s solution in Graves’ disease and toxic nodular goiter
EU CTIS ID: 2024-517110-15-00
What this study is testing
Pilot study: To investigate the effect of iodine solution on toxic nodular goiter. Can it be administered safely to patients with toxic nodular goiter? How are the thyroid hormones and clinical status affected? Main study: Does preoperative treatment with iodine solution reduce the postoperative risk of temporary hypoparathyroidism in patients with toxic nodular goiter and Graves' disease undergoing thyroidectomy?
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Pilot study: Hyperthyroidism due to toxic nodular goiter. Age 18-75 years. Main study: Hyperthyroidism due to toxic nodular goiter and Grave's disease accepted for thyroidectomy. Age 18-75 years.
You likely can't join if
- Unstable coronary artery disease Previous thyroid surgery Congestive heart failure Renal failure Liver failure Current infection Ongoing treatment with glucocorticoids Ongoing treatment with anticoagulants Thyroid associated ophtalmopathy CAS >2 Diabetes mellitus type1 Active cancer Severe psychiatric illness Amiodarone treatment Pregnancy Breast feeding Women with childbearing potential not using contraception Unability to comprehend the meaning of the study Iodine hypersensitivity
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.